Biopharmaceutical News and Research

RSS

Halo Healthcare acquires assets of NeoMatrix

Halo Healthcare, Inc. announces it has acquired the assets of NeoMatrix, LLC and has restructured the Company, including engaging a new CEO and management team, appointing a new Board of Directors, and relaunching the HALO diagnostic device for breast cancer risk assessment.

24 May 2012

USPTO issues patent to MicuRx’s MRX-I antibacterial agent

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office (USPTO) issued a composition of matter patent covering its clinical candidate, MRX-I. MRX-I is a novel antibacterial oxazolidinone that targets infections due to multi-drug resistant Gram-positive pathogens.

23 May 2012

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider of diagnostic reagents.

23 May 2012

HVTN opens enrollment in GeoVax’s GM-CSF adjuvanted vaccine Phase 1 trial for HIV

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that the NIH-funded HIV Vaccine Trials Network (HVTN) has opened enrollment for a Phase 1 trial for the company's second-generation HIV vaccine.

23 May 2012

Researchers identify new mechanism for drug-related autoimmune reactions

A team of researchers led by the U.S. Food and Drug Administration has discovered a new mechanism for identifying and understanding drug-related autoimmune reactions.

23 May 2012

Ocera’s Zysa receives CE Mark to treat IBS-d

Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.

19 May 2012

Additional data from Tokai’s galeterone Phase 1 study on CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that additional data from a Phase 1 safety and proof-of-concept study evaluating lead candidate, galeterone, in patients with castration-resistant prostate cancer (CRPC) will be highlighted in a poster presentation titled, "Phase I clinical trial of galeterone, a multifunctional anti-androgen and CYP17 inhibitor in castration resistant prostate cancer," abstract number 4665, on Sunday, June 3, 2012, 8:00 a.m. to 12:00 p.m. at the 2012 Annual Meeting of the American Society of Clinical Oncology.

18 May 2012

First patient included in the phase II study of Amphinex® in head and neck cancer patients

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).

16 May 2012

Nile reports net operating loss of $0.8M for first quarter 2012

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its first quarter financial results for 2012.

16 May 2012

Sinovac first quarter sales increase 30.3% to $6.0M

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012.

15 May 2012

Soligenix first quarter revenues decrease to $647,418

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the quarter ending March 31, 2012.

14 May 2012

S1 Biopharma announces foray into male sexual health with S1P-205

S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions, today announced its foray into male sexual health with S1P-205, the first and only drug in development for male HSDD.

14 May 2012

3SBio first quarter total net revenues increase 24.5% to RMB147.2M

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2012.

14 May 2012

BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the second wave of its LaunchTrends® Yervoy and Zelboraf report, in which 103 U.S.-based medical oncologists were surveyed about their current and expected treatment patterns in advanced melanoma.

11 May 2012

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that analysis of U.S. longitudinal patient-level claims data reveals the use of Bristol-Myers Squibb's oral Abilify as a first-line therapy for newly diagnosed schizophrenia patients continues to grow.

10 May 2012

Orexigen reports net loss of $10.4 million for first quarter 2012

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2012.

10 May 2012

Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

9 May 2012

BioDiem announces new vaccine research collaboration with French-based VIVALIS

Australian vaccine development company BioDiem Ltd (ASX: BDM) today announced that it has begun a research collaboration with France-based VIVALIS (Euronext code: VLS), a biopharmaceutical company with expertise in vaccine production technologies.

9 May 2012

ACADIA first quarter net loss increases to $6.2 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2012.

9 May 2012